Oramed rises as enrollment hits 50% in late-stage oral insulin trial

Oramed Pharmaceuticals

26/07/2022 14:09

** Oramed Pharmaceuticals' shares  ORMP.O  up 3.9% at $7.94
premarket
    ** Says co reached 50% enrollment in its 450-patient second
late-stage trial of oral insulin for treatment of type 2
diabetes  urn:newsml:reuters.com:*:nPnX2xGja
    ** Data from the first late-stage trial, which is larger,
expected in January 2023
    ** All four brokerages covering ORMP rate the stock "buy" or
higher; their median PT is $31
    ** Stock down 46% this year, up to last close

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))